Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Induced pluripotent stem cells without viral vectors

This article was originally published in Scrip

Executive Summary

The Japanese team which generated induced pluripotent stem (iPS) cells from normal human skin cells last year has developed a new virus-free technique. Professor Shinya Yamanaka and others at Kyoto University successfully transfected mouse embryonic fibroblasts with the requisite genes using plasmids rather than retroviral or lentiviral vectors. These can become integrated into the genome, increasing the risk of cancer. The technique so far has a lower production efficiency and has not been applied to somatic cells. iPS cells behave like embryo-derived stem cells but with none of the ethical and immunogenicity concerns, and may in future be used in novel regenerative therapies.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC030472

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel